According to CNBC, Nome, a startup positioning itself as a contract research organization for smaller rare disease groups, is using AI to help families and patient organizations identify possible treatment paths after a genetic diagnosis. The company says it can analyze uploaded test results in about 10 minutes, then provide a free report that outlines potential options, trial design and next steps.

Founder and CEO Stevie Ringel said Nome currently produces 80 to 100 reports a month and has reviewed about 5,000 cases to date, identifying a programmable medicine or existing custom therapy that matches the known mutation roughly 25% of the time. He said the company oversees a little more than 10 genetic medicine programs and automates about 25% of its work with AI, with a goal of automating 60% to 80% of the process over the next one to two years.

Ringel said a customized ASO costs between $1.2 million and $1.4 million, and he hopes Nome can cut that cost by 50% to make individualized therapies more accessible. He said the company makes money when customers hire it to design clinical trials or manage the process through dosing.